CClinicalTrials.gg
CompletedNCT02969395Updated Aug 22, 2022

3T MRI CIED Post-Approval Study

An observational study in Cardiac Rhythm Disorder, sponsored by Medtronic. Completed at 204 sites in 22 countries. Per ClinicalTrials.gov, last updated 2022-08-22.

Sponsored by Medtronic · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
41
Sex
All
01

Study summary

The purpose of this study is to evaluate product performance of Magnetic Resonance (MR) Conditional Cardiac Implantable Electronic Devices (CIED) following 3 tesla (3T) MRI exposure. This will be achieved by evaluating the changes in pacing capture threshold (PCT) measurements following 3T MRI scan exposure. This study is required by FDA as a condition of approval of 3T MRI compatible labeling of applicable CIED systems. This study is conducted within Medtronic's post-market surveillance platform, the Product Surveillance Registry (PSR).

02

Conditions studied

  • Cardiac Rhythm Disorder

Browse trials for

Keywords

  • 3T
  • Magnetic Resonance Imaging (MRI)
  • Implantable Cardioverter Defibrillator (ICD)
  • Implantable Pulse Generator (IPG)
  • Cardiac Resynchronization Therapy (CRT)
  • Cardiac Implantable Electronic Device (CIED)
03

In context

Arrhythmias, Cardiac

885 studies on the registry are indexed under Arrhythmias, Cardiac; 235 are open to participants now.

This study's enrollment of 41 is below the median of 200 across 414 observational studies indexed under Arrhythmias, Cardiac.

Browse Arrhythmias, Cardiac studies →

Lead sponsor

Medtronic is the lead sponsor of 42 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients intended to be implanted or are within 30 days post-implant of a qualifying Medtronic 3T MR Conditional CIED system. All subjects must meet Inclusion criteria and none of the Exclusion criteria.

Inclusion criteria

  • Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  • Subject is intended to be implanted or is within 30 days post-implant of a qualifying Medtronic 3T MR Conditional CIED system

Exclusion criteria

Exclusion Criteria:

  • Subject who is, or will be inaccessible for follow-up at a study site
  • Subject with exclusion criteria required by local law (Europe, Central Asia [ECA] only)
  • Implant and follow-up data, including any adverse device effects and system modifications at implant through the time of enrollment are unavailable
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
41 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. The proportion of patients implanted with an MR Conditional CIED System with a pre-MRI to post-MRI scan PCT measure change of >0.5 Volts following 3T MRI scan exposure.

    Time frame: Patients will be followed for approximately 5 years.

07

Study locations

204 sites
  • Birmingham, Alabama, United States
  • Anchorage, Alaska, United States
  • Chandler, Arizona, United States
  • Jonesboro, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Bakersfield, California, United States
  • Chula Vista, California, United States
  • La Quinta, California, United States
  • Los Angeles, California, United States
  • Palm Springs, California, United States
  • Rancho Mirage, California, United States
  • Redwood City, California, United States
  • Salinas, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Stanford, California, United States
  • Torrance, California, United States
  • Van Nuys, California, United States
  • Centennial, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Lakewood, Colorado, United States
  • New Haven, Connecticut, United States
  • Newark, Delaware, United States
  • Washington, District of Columbia, United States
  • Bradenton, Florida, United States
  • Clearwater, Florida, United States
  • Davenport, Florida, United States
  • Davie, Florida, United States
  • Jacksonville, Florida, United States
  • Panama City, Florida, United States
  • Safety Harbor, Florida, United States
  • Sebastian, Florida, United States
  • Tampa, Florida, United States
  • Albany, Georgia, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Coeur d'Alene, Idaho, United States
  • Chicago, Illinois, United States
  • Evansville, Indiana, United States
  • Indianapolis, Indiana, United States
  • West Des Moines, Iowa, United States
  • Kansas City, Kansas, United States
  • Edgewood, Kentucky, United States
  • Louisville, Kentucky, United States
  • Baton Rouge, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Baltimore, Maryland, United States
  • Clinton, Maryland, United States
  • Hyattsville, Maryland, United States
  • Salisbury, Maryland, United States
  • Silver Spring, Maryland, United States
  • Takoma Park, Maryland, United States
  • Boston, Massachusetts, United States
  • Lansing, Michigan, United States
  • Marquette, Michigan, United States
  • Ypsilanti, Michigan, United States
  • Coon Rapids, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • Robbinsdale, Minnesota, United States
  • Rochester, Minnesota, United States
  • Saint Cloud, Minnesota, United States
  • Saint Louis Park, Minnesota, United States
  • Saint Paul, Minnesota, United States
  • Hattiesburg, Mississippi, United States
  • Columbia, Missouri, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Henderson, Nevada, United States
  • Eatontown, New Jersey, United States
  • Morristown, New Jersey, United States
  • Ocean Township, New Jersey, United States
  • Ridgewood, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Bay Shore, New York, United States
  • Bronx, New York, United States
  • Garden City, New York, United States
  • Huntington, New York, United States
  • Manhasset, New York, United States
  • New Hyde Park, New York, United States
  • New York, New York, United States
  • Poughkeepsie, New York, United States
  • Staten Island, New York, United States
  • Suffern, New York, United States
  • Utica, New York, United States
  • Durham, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Akron, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Allentown, Pennsylvania, United States
  • Bethlehem, Pennsylvania, United States
  • Danville, Pennsylvania, United States
  • Erie, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States

Showing the first 100 of 204 sites across 22 countries.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02969395
Lead sponsor
Medtronic
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Apr 2016
Primary completion
Oct 15, 2021
Completion
Oct 15, 2021
Last update
Aug 22, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion